Mechanisms of Mitochondrial Defects in Gulf War Syndrome

Overview

The purpose of the study is to investigate possible causes for Gulf War Syndrome. Gulf War Syndrome is associated with increased incidences of amyotrophic lateral sclerosis (Lou Gehrig's Disease), pain syndromes, muscle complaints that include fatigue and myalgias (muscle pain), as well as other neurological symptoms. Abnormalities in the part of the cell known as mitochondria have been delineated in Gulf War Syndrome. Mitochondria are the "power plants" of the body. Mitochondria take the food you eat and break the food down into a form of energy that the body can use. The investigators propose that Gulf War Syndrome is determined by a complex interaction of factors that interfere with mitochondrial function. This study will be the first investigation of mitochondrial function in Gulf War Syndrome. The investigators objective is to establish the cause for symptoms in affected veterans, develop testing that can more easily identify Gulf War Syndrome, and ultimately develop treatment protocols for Gulf War Syndrome.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 2013

Interventions

  • Procedure: Skin biopsy
    • A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
  • Procedure: Blood Collection
    • Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient’s forearm.

Arms, Groups and Cohorts

  • Gulf War Syndrome patients
    • Gulf War veterans who have been diagnosed with Gulf War Syndrome.

Clinical Trial Outcome Measures

Primary Measures

  • Characterize mitochondrial cellular energetics in Gulf War Syndrome patients
    • Time Frame: approximately 2 years; once all data has been collected from study participants
    • After collecting a skin and blood sample, mitochondrial cellular energetics in Gulf War Syndrome patients will be characterized by: 1. high resolution respirometry of intact cells, 2. quantitative analysis of individual mitochondrial proteins, 3. analysis of intact OXPHOS enzyme complexes and supercomplexes, 4. in gel enzyme activity assessment of intact OXPHOS enzyme complexes and supercomplexes, 5. mitochondrial DNA (mtDNA) copy number quantitation to assess for defects in regulation mtDNA replication and 6. cellular coenzyme Q10 quantitation.

Secondary Measures

  • Mitochondrial DNA
    • Time Frame: approximately 2 years; once all data has been collected from study participants.
    • Assess the mitochondrial DNA (mtDNA) from each patient with Gulf War Syndrome for mtDNA mutations by whole genome sequencing of leukocyte and skin cell mtDNA.

Participating in This Clinical Trial

Inclusion Criteria

  • Short-term memory loss or a severe inability to concentrate that affects work, school or other normal activities
  • Muscle Pain, myalgias
  • Pain without redness or swelling in a number of joints
  • Intense or changing patterns of headaches
  • Unrefreshing sleep
  • After any exertion, weariness that lasts for more than a day

Exclusion Criteria

  • Organ failure (e.g. emphysema, cirrhosis, cardiac failure, chronic renal failure)
  • Chronic infections (e.g. HIV/AIDS, hepatitis B or C)
  • Rheumatic and chronic inflammatory diseases (e.g. systemic lupus erythematosis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease, chronic pancreatitis.)
  • Major neurologic diseases (e.g. multiple sclerosis, neuromuscular diseases, epilepsy or other disease requiring ongoing medication that could cause fatigue, stroke, head injury with residual neurologic deficits)
  • Diseases requiring systemic treatment (e.g. organ or bone marrow transplantation; systemic chemotherapy; radiation of brain, thorax, abdomen, or pelvis)
  • Major endocrine diseases (e.g. hypopituitarism, adrenal insufficiency)
  • Myocardial infarction, heart failure
  • Morbid obesity (body mass index >40)
  • Permanent psychiatric exclusions: Lifetime diagnoses of bipolar affective disorders, schizophrenia or any subtype, delusional disorders of any subtype, dementias of any subtype, organic brain disorders, and alcohol or substance abuse within 2 years before onset of the fatiguing illness.
  • History of allergic reaction to lidocaine
  • History of keloid formation with skin incisions.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medical Neurogenetics, LLC
  • Collaborator
    • United States Department of Defense
  • Provider of Information About this Clinical Study
    • Principal Investigator: John M. Shoffner, Medical Director – Medical Neurogenetics, LLC
  • Overall Official(s)
    • John M Shoffner, MD, Principal Investigator, Medical Neurogenetics

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.